VERU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Veru Inc (VERU) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has some potential in the biotech space with its obesity drug development pipeline, the lack of immediate positive catalysts, weak financial performance, and neutral trading sentiment suggest holding off on investment until more favorable conditions arise.
The MACD is positive and expanding, indicating a potential upward momentum. RSI is in the neutral zone at 75.454, and moving averages are converging, suggesting no clear trend. The pre-market price is $2.66, up 2.63%, and the stock is near its first resistance level (R1: 2.644).
The company is positioned as a differentiated biotech in obesity drug development, with promising Phase IIb trials for its lead candidate, enobosarm. Analysts have initiated coverage with a Buy rating and a $25 price target, indicating long-term potential.
Weak financial performance in the latest quarter, with revenue at $0 and a significant YoY drop in net income (-40.39%) and EPS (-57.38%). No significant insider or hedge fund activity, no recent news, and no congress trading data to suggest strong interest in the stock.
In Q1 2026, Veru reported $0 revenue, with net income dropping to -$5,332,579 (-40.39% YoY) and EPS declining to -0.26 (-57.38% YoY). Gross margin remained at 0%. The financials indicate significant challenges in profitability and growth.
Canaccord initiated coverage with a Buy rating and a $25 price target, citing Veru's differentiated approach in obesity drug development. However, the timeline for clinical trial results (1H28) suggests a long wait for potential catalysts.
